BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results an ...

Core Viewpoint - BrainsWay Ltd. has announced that Premera Blue Cross Blue Shield has adopted a new medical policy expanding coverage for patients aged 15 and older with moderate to severe major depressive disorder treated with BrainsWay's SWIFT Deep TMS protocol, marking a significant development in insurance coverage for this treatment [1][2]. Group 1: Company Developments - The SWIFT depression protocol consists of five treatment sessions per day for six days, followed by two sessions per day once a week for four weeks, totaling 38 sessions, and does not require expensive neuronavigational equipment [3]. - BrainsWay's clinical trials and real-world evidence show comparable response and remission outcomes for the SWIFT protocol compared to the standard Deep TMS protocol, indicating its effectiveness [4]. - The company continues to lead in the field with its proprietary H-coil technology and is focused on expanding access to advanced neurostimulation therapies through collaboration with providers and policymakers [5]. Group 2: Company Background - BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS platform that has received FDA clearance for multiple indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [6]. - The company was founded in 2003 and operates in the United States and Israel, with ongoing clinical trials for various psychiatric, neurological, and addiction disorders [6].

Core Insights - BrainsWay Ltd. achieved record quarterly sales of $11.4 million in Q4 2024, marking a 27% increase compared to Q4 2023 [1][4] - The full year 2024 revenue rose nearly 30% year-over-year to $41 million [1][4] - The company exceeded its full year 2024 operating income and Adjusted EBITDA margin guidance [1] - For 2025, BrainsWay expects continued strong growth, projecting revenue between $49 million and $51 million, indicating a growth of 20% to 24% over 2024 [1][10] Q4 2024 Financial Highlights - Q4 2024 revenue was $11.4 million, a 27% increase from Q4 2023 [4] - A total of 75 Deep TMS™ systems were shipped, a 25% increase from the previous year [4] - Gross margin for Q4 2024 remained at 75%, consistent with the prior year [4] - Operating income for Q4 2024 was $0.4 million, up from $0.2 million in Q4 2023 [4] - Adjusted EBITDA for Q4 2024 was approximately $1.4 million, compared to $0.8 million in Q4 2023 [4] - Net income for Q4 2024 was $1.5 million, significantly higher than $0.1 million in Q4 2023 [4] Full Year 2024 Financial Highlights - Full year 2024 revenue reached $41 million, a 29% increase from 2023 [4] - Gross margin for the full year was 75%, slightly up from 74% in the previous year [4] - Operating income for the full year was $1.4 million, a turnaround from a loss of $5 million in 2023 [4] - Net income for the full year was $2.9 million, compared to a net loss of $4.2 million in 2023 [4] - Adjusted EBITDA for the full year was approximately $4.5 million, compared to an adjusted EBITDA loss of $2.4 million in the prior year [4] Strategic Developments - The company completed a $20 million strategic equity financing transaction with Valor Equity Partners [4] - As of December 31, 2024, cash and cash equivalents totaled $69.4 million, a significant increase from $10.5 million in 2023 [4][19] - BrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, broadening the age range for treatment [4] - The company reported a significant increase in Deep TMS treatments for anxious depression in the second half of 2024, addressing a large medical condition affecting millions in the U.S. [4] 2025 Financial Guidance - BrainsWay anticipates revenue for 2025 to be between $49 million and $51 million, representing a growth of 20% to 24% over 2024 [10] - The company targets an operating income of 3% to 4% and an Adjusted EBITDA of 11% to 12% for the full year 2025 [10]